The clinical pillar that shifts the logic from replacing what is damaged to repairing what is damaged. Where conventional medicine operates, prosthesis, or resection, the regenerative approach asks whether tissue still has biological capacity for self-repair and works to activate it — under individual medical criteria and always within the applicable regulatory framework.
It is one of the three clinical pillars at Wellness Care, alongside functional medicine and biological medicine. Here we explain what science says today about mesenchymal stem cells (MSC) and exosomes — paracrine mechanisms, hypoxia culture, available clinical evidence, and global regulatory status — plus the operational comparison vs the conventional model.
Surgery and prosthesis are essential when tissue has lost all capacity for self-repair. But in partial damage — degraded cartilage, inflamed tendon, post-surgical wound, chronic immune fatigue — regenerative medicine works on mechanisms that conventional medicine rarely evaluates.
Regenerative medicine does not compete with surgery — it complements or precedes it in patients with partial damage. In Colombia, the use of stem cells and exosomes in humans requires case-by-case evaluation under the applicable regulatory framework (INVIMA). Indication is determined in individual medical consultation.
The original idea of MSC therapies was grafting: introduce stem cells that would differentiate into the damaged tissue and replace it. Modern evidence points to a very different mechanism — injected MSCs rarely survive more than a few days, but during that time they secrete a cocktail of paracrine factors that modulate the local environment.
They reduce inflammation, stimulate resident cells, modulate immune response. The conceptual shift — from "cell transplant" to "paracrine signaling" — reorients the entire field.
What matters isn't necessarily the live cell, but what the cell secretes. That's the biological foundation of the next category: exosomes.
MSCs derived from umbilical cord, adipose tissue, or bone marrow have distinct secretome profiles. Umbilical source (young donors) typically shows greater proliferative potency and a better immunomodulatory profile.
MSCs cultured in low oxygen — closer to their physiological niche — show greater proliferative capacity, better phenotype preservation, and a secretome enriched in anti-inflammatory factors.
MSCs lose potency with each passage. Early passages have a better profile. Minimum ISCT characterization (CD73+, CD90+, CD105+ ; CD34-, CD45-, HLA-DR-) and documented functional potency.
Production under Good Manufacturing Practice with donor traceability, microbiological controls, documented viability, and certificates of analysis. Without GMP, no clinical result is interpretable.
Exosomes are 30–150 nm extracellular vesicles that MSCs (and virtually all cells) secrete. They carry microRNA, proteins, and lipids that act as messengers between cells. Recent research suggests much of the therapeutic effect observed with MSCs could be explained by the exosomes they release, not the cells themselves.
If exosomes are the active messengers, they could in principle be used without transplanting live cells — with a potentially better safety profile: they don't replicate, don't engraft, don't cause rejection. It's a young and hot field.
Quality and characterization criteria are actively debated. ISEV publishes regular guidelines on minimum characterization — reading them is mandatory before any clinical consideration.
Cellular products approved only for specific indications (oncology). MSCs for longevity or general regenerative indications are not approved; FDA issued 2017–2020 guidelines restricting clinics without IND.
Advanced Therapy Medicinal Products (ATMP) under specific regulation. Specific approvals: Alofisel for perianal fistula, Holoclar for cornea.
Accelerated regulatory framework allowing earlier conditional approvals. International reference model for advanced therapies in evolution.
Evolving regulatory framework. Cellular therapies and exosomes do not have formal approval for general therapeutic use at the time of this publication.
Three data points that moved from promise to reproducible evidence — and the technical criteria that separate a serious product from one without traceability.
"More than 1,000 registered clinical trials evaluate mesenchymal stem cells across inflammation, autoimmunity, joint, and neurodegenerative pathologies."1,000+ trials · clinicaltrials.gov
"MSCs showed an overall response rate above 70% in patients with graft-versus-host disease refractory to first-line treatments.">70% response · GVHD · refractory
"Minimum ISCT (MSC) and ISEV (exosome) criteria — the technical foundation to distinguish a serious product from one without GMP traceability."ISCT · ISEV · GMP traceability
The recurring questions about mesenchymal stem cells and exosomes — what they are, MSC vs. exosomes, FDA approval, hypoxia culture, regulatory status in Colombia, source comparisons, and protocol costs. Answers aligned with indexed literature.
MSCs are multipotent cells that can differentiate into connective tissue cells (bone, cartilage, fat), but whose main modern therapeutic effect is attributed to paracrine signaling — they secrete growth factors, cytokines, and exosomes that modulate inflammation, stimulate resident cells, and modulate immune response.
Main sources: umbilical cord (Wharton's jelly), adipose tissue, and bone marrow.
MSCs are living cells that secrete therapeutic factors during the few days they survive after infusion.
Exosomes are 30–150 nm extracellular vesicles — the molecular messengers MSCs release — loaded with microRNA, proteins, and lipids.
Recent research suggests much of the therapeutic effect of MSCs may be explained by the exosomes they release, not by the living cells. Exosomes do not replicate, do not engraft, and do not cause rejection.
The FDA approves a very limited number of cellular products for specific indications (mostly oncology).
MSCs and exosomes for longevity or general regenerative indications are NOT FDA-approved. The FDA issued 2017–2020 guidance actively restricting clinics offering MSCs without IND (Investigational New Drug).
MSCs in their physiological niche operate at low oxygen levels (1–5%), not the 21% of conventional normoxic culture.
Culturing MSCs in hypoxia activates the HIF-1α factor and produces a significantly more potent secretome — greater proliferative capacity, better phenotype preservation, and enrichment in anti-inflammatory and pro-angiogenic factors.
The difference between normoxic and hypoxic MSCs is clinically significant.
The regulatory framework for cellular therapies and exosomes in Colombia is evolving. INVIMA has not issued formal approval for general therapeutic use of MSCs and exosomes in longevity indications at the time of this publication.
Wellness Care's editorial content on regenerative medicine is a scientific review of the global state of the art — not a treatment offering. Any concrete therapeutic consideration must be framed within the applicable regulatory context and under individual medical criteria.
Each source has distinct secretome profiles.
· Umbilical cord MSCs (Wharton's jelly) typically show greater proliferative potency, better immunomodulatory capacity, and come from young donors — preferred for longevity protocols.
· Bone marrow MSCs (autologous) are useful for musculoskeletal indications.
· Adipose MSCs are easy to obtain but their secretome varies with donor age and metabolic status.
Costs vary by cellular source, dose, number of sessions, and jurisdiction. In typical international clinics: USD 5,000–25,000 per MSC session, USD 2,000–8,000 per exosome session.
Wellness Care does not publish standard prices — content on these therapies is educational. Any therapeutic consideration must be framed within the applicable regulatory context and under individualized medical evaluation.
Cellular regeneration is not science fiction — it's biochemistry with a name, a mechanism and evidence. What nature designed to repair itself, we can today learn, replicate and apply under medical criteria.
Recovering functional capacity, modulating chronic inflammation and activating regenerative signaling is possible with the right molecules, the right dose, and the GMP traceability that evidence demands. No shortcuts, no empty promises.
We evaluate your clinical situation, biomarkers, and objectives. We explain what the evidence says for a profile like yours, what the applicable regulatory framework is, and what realistic options exist — no promises, no pressure, under strict medical criteria.
Schedule consultation about regenerative medicine